Pioneering the Next Generation of Antibody Therapeutics

Antibody render
DegrAb™

Mission

We founded LuMiAL Bio to transform loss into hope by developing better antibody therapies for cancer and autoimmune diseases, so that no one else has to face these diseases without options. We are here to bring innovation, compassion, and cures to patients before it is too late.

Founders

Portrait of Miguel E. Moreno-Garcia

Miguel E Moreno-Garcia, PhD

Co-Founder

Miguel Moreno-Garcia, Ph.D., brings over 20 years of experience in immunology and drug discovery across academia and the biopharmaceutical industry. Miguel earned his PhD in Cell Biology from CINVESTAV, with training at the Trudeau Institute and UCLA School of Medicine. Miguel completed postdoctoral fellowships at the University of Washington and Seattle Children’s Research Institute.

Miguel has led discovery programs at Boehringer Ingelheim and Pfizer, advancing biotherapeutics that target immune-modulatory pathways in autoimmune disease, oncology, and fibrosis, with deep expertise in B-cell biology and biomarker strategy.

LinkedIn

Portrait of Lucrecia Marquez-Rosado

Lucrecia Márquez-Rosado, MD, PhD.

Co-Founder

Lucrecia Marquez-Rosado, M.D., Ph.D., is a physician-scientist with over 20 years of experience in oncology, immunology, and drug discovery in both academia and biotech. She completed clinical training at the Salvador Zubirán National Institute, earned a Ph.D. in Cell Biology from CINVESTAV, and finished a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center. Before co-founding LuMiAL Bio, she held scientific roles at Boehringer Ingelheim, SIBTECH, and Nurix Therapeutics, where she led cross-functional teams involved in translational research programs.

Lucrecia brings extensive expertise in targeted protein degraders and small-molecule discovery, biomarker and disease-positioning strategies, and progressing therapeutic programs from target validation through the discovery pipeline.

LinkedIn

Get in touch

Events

AI-Powered Innovation in Protein & Antibody Therapeutics Symposium

LuMiAL Bio oral presentation at AI-Powered Innovation in Protein & Antibody Therapeutics Symposium (AIPAT 2025), organized by Sino Biological

Panel: AI in Biologics Manufacturing (BioFuture 2025)

LuMiAL Bio poster presentation at MBC BioLabs Oncology Innovation Forum

Poster: Deep Learning for Antibody Optimization (NeurIPS Bio-ML 2025)

LuMiAL Bio Participates in the 23rd BioPharma Drug Discovery Nexus Conference

© LuMiAL Bio. All rights reserved.